Given the current lack of therapies proven to reduce morbidity and mortality in patients with heart failure and CKD, our results support the hypothesis that pharmacological modulation of LCAT strengthens the case for potential treatment for ADHF in patients with CKD. This evidence concerns the gene LCAT and chronic kidney disease.